切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (03) : 176 -180. doi: 10.3877/cma.j.issn.2095-3232.2015.03.011

所属专题: 文献

临床研究

他克莫司缓释胶囊在肝移植术后患者中的应用价值
许世磊1, 张英才1, 王庆亮2, 杨卿1, 汪国营1, 刘波2, 陈文捷3, 杨扬1,(), 陈规划1   
  1. 1. 510630 广州,中山大学附属第三医院肝移植中心
    2. 510530 广州,中山大学附属第三医院岭南医院普通外科
    3. 广东省肝脏疾病研究重点实验室
  • 收稿日期:2015-03-12 出版日期:2015-06-10
  • 通信作者: 杨扬
  • 基金资助:
    国家自然科学基金(81170451,81301331); 广东省科技计划项目(2011B031800103); 广东省自然科学基金重点项目(9251008901000025); 广州市科技计划重点项目(2011Y1-00033)

Application value of Tacrolimus sustained-release capsules in patients after liver transplantation

Shilei Xu1, Yingcai Zhang1, Qingliang Wang2, Qing Yang1, Guoying Wang1, Bo Liu2, Wenjie Chen3, Yang Yang1,(), Guihua Chen1   

  1. 1. Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Department of General Surgery, Lingnan Hospital, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510530, China
    3. Guangdong Provincial Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2015-03-12 Published:2015-06-10
  • Corresponding author: Yang Yang
  • About author:
    Corresponding author: Yang Yang, Email:
引用本文:

许世磊, 张英才, 王庆亮, 杨卿, 汪国营, 刘波, 陈文捷, 杨扬, 陈规划. 他克莫司缓释胶囊在肝移植术后患者中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(03): 176-180.

Shilei Xu, Yingcai Zhang, Qingliang Wang, Qing Yang, Guoying Wang, Bo Liu, Wenjie Chen, Yang Yang, Guihua Chen. Application value of Tacrolimus sustained-release capsules in patients after liver transplantation[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(03): 176-180.

目的

探讨他克莫司缓释胶囊在肝移植术后患者中的应用价值。

方法

回顾性研究2011年1月至2013年12月在中山大学附属第三医院接受诊治的48例肝移植术后患者临床资料。所有患者均签署知情同意书,符合医学伦理学规定。其中男43例,女5例;平均年龄(45±12)岁。根据术后有否应用他克莫司缓释胶囊将患者分为缓释组(18例)和对照组(30例)。两组患者术后早期均采用他克莫司+甲泼尼龙二联免疫抑制方案。缓释组术后20 d开始改用等剂量他克莫司缓释胶囊。比较两组患者他克莫司血药浓度谷值的变化及排斥反应和不良反应的发生率。两组他克莫司血药浓度谷值比较采用t检验;排斥反应及不良反应发生率比较采用χ2检验或Fisher确切概率法。

结果

缓释组患者血药浓度谷值逐渐下降并于30 d趋于稳定,对照组血药浓度谷值波动较大。缓释组60 d时血药浓度谷值为(7±2) μg/L,明显低于对照组的(10±1) μg/L(t=-15.61,P<0.05)。缓释组排斥反应的发生率为0(0/18),明显低于对照组的7%(2/30) (P<0.05)。缓释组肺炎、消化道症状、高血糖、睡眠障碍的发生率分别为33%(6/18)、28%(5/18)、6%(1/18)、6%(1/18),明显低于对照组的77%(23/30)、37%(11/30)、17%(5/30)、23%(7/30) (χ2=18.90,31.53,12.41,45.19;P<0.05)。

结论

肝移植术后患者应用他克莫司缓释胶囊可以维持稳定的他克莫司血药浓度谷值,具有良好的抗排斥疗效,并可降低不良反应发生率。

Objective

To investigate the application value of Tacrolimus sustained-release capsules in patients after liver transplantation (LT).

Methods

Clinical data of 48 patients after LT treated in the Third Affiliated Hospital of Sun Yat-sen University between January 2011 and December 2013 were retrospectively studied. The informed consents of all patients were obtained and the local ethical committee approval had been received. Among the 48 patients, 43 were males and 5 were females with an average age of (45±12) years old. According to whether Tacrolimus sustained-release capsules were given after LT, the patients were divided into sustained-release group (18 patients) and control group (30 patients). The patients in both groups received combined immunosuppressive therapy of Tacrolimus + Methylprednisolone in the early stage after operation. Patients in sustained-release group were given Tacrolimus sustained-release capsules of equivalent dose 20 d after LT. The changes of plasma valley concentration of Tacrolimus and the incidence of rejection and adverse reactions of the two groups were compared. The comparison of plasma valley concentration of Tacrolimus was conducted using t test, and the comparison of incidence of rejection and adverse reactions was conducted using Chi-square test or Fisher's exact test.

Results

The plasma valley concentration of sustained-release group decreased gradually and stabilized after 30 d, while that of control group fluctuated widely. On 60 d, the plasma valley concentration of sustained-release group was (7±2) μg/L, which was significantly lower than (10±1) μg/L of control group (t=-15.61, P<0.05). The incidence of rejection of sustained-release group was 0 (0/18), which was significantly lower than 7% (2/30) of control group (P<0.05). The incidence of pneumonia, gastrointestinal symptoms, hyperglycemia and sleep disorders of sustained-release group was respectively 33% (6/18), 28% (5/18), 6% (1/18) and 6% (1/18) , which was significantly lower than 77% (23/30), 37% (11/30), 17% (5/30) and 23% (7/30) of control group (χ2=18.90, 31.53, 12.41, 45.19; P<0.05).

Conclusions

The application of Tacrolimus sustained-release capsules in patients after LT can maintain stable plasma valley concentration of Tacrolimus, have good anti-rejection effect and reduce the incidence of adverse reactions.

表1 缓释组和对照组肝移植术后患者一般资料比较
表2 缓释组和对照组肝移植术后患者血ALT比较(U/L,±s
表3 缓释组和对照组肝移植术后患者血AST比较(U/L,±s
表4 缓释组和对照组肝移植术后患者Scr比较(μmol/L,±s
表5 缓释组和对照组肝移植术后患者他克莫司血药浓度谷值的比较(μg/L,±s
表6 缓释组和对照组肝移植术后患者排斥反应及不良反应的比较(例)
[1]
栗光明,郑树森,刘永锋,等.他克莫司胶囊和缓释胶囊预防肝移植急性排斥反应的效果和安全性[J].中华器官移植杂志,2011, 32(4):217-220.
[2]
石炳毅,韩文科,张小东,等.肾移植术后将环孢素A切换为他克莫司缓释胶囊的临床研究[J].中华器官移植杂志,2014, 35(2): 77-81.
[3]
郑卫萍.缓释他克莫司、他克莫司、环孢素分别联合吗替麦考酚酯3种治疗方案在首次肾移植患者中比较的Ⅲ期临床试验远期随访结果[J/CD].实用器官移植电子杂志,2014,2(3):166.
[4]
柯于海,张振伟,冯登殿,等.不同时段应用他克莫司纳米微球缓释颗粒促进同种异体神经移植再生的实验研究[J].中华手外科杂志,2010, 26(4): 230-233.
[5]
Thölking G, Fortmann C, Koch R, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation[J]. PLoS One, 2014, 9(10): e111128.
[6]
石伟龙,唐惠林,胡永芳.系统评价肝移植受者使用他克莫司缓释剂型与普通剂型的有效性与安全性[J].中国临床药理学杂志,2014, 30(8): 727-729.
[7]
张逸凡,陈笑艳,戴晓健,等.比较他克莫司缓释制剂与普通制剂在中国肾移植患者的药代动力学[J].中国临床药理学杂志,2011,27(9):696-700.
[8]
Meçule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors[J]. Transplant Proc, 2010, 42(4):1317-1319.
[9]
Souto-Rodríguez R, Molina-Pérez E, Castroagudín JF, et al. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol[J]. Transplant Proc, 2014, 46(9):3117-3120.
[10]
Mccormack PL. Extended-release tacrolimus: a review of its use in de novo kidney transplantation[J]. Drugs, 2014, 74(17):2053-2064.
[11]
Sańko-Resmer J, Boillot O, Wolf P, et al. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study[J]. Transpl Int, 2012, 25(3): 283-293.
[12]
Giannelli V, Rossi M, Giusto M, et al. Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up[J]. Eur Rev Med Pharmacol Sci, 2013, 17(20): 2718-2720.
[13]
Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient[J]. Transplant Proc, 2010, 42(4):1322-1324.
[14]
Comuzzi C, Lorenzin D, Rossetto A, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients[J]. Transplant Proc, 2010, 42(4):1320-1321.
[15]
Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-Year post-conversion in stable pediatric liver transplant recipients[J]. Am J Transplant, 2007, 7(6):1609-1615.
[16]
Umbro I, Tinti F, Mecule A, et al. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients[J]. Transplant Proc, 2012, 44(7):1907-1909.
[17]
Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients[J]. Transplantation, 2011, 92(6):648-652.
[18]
吕海金,易慧敏.实体器官移植受者的免疫功能测定研究进展[J].器官移植,2014, 5(4):257-260.
[19]
王建立,范宁,王颖,等.肝移植术后慢性肾功能损伤的危险因素分析[J].中华消化外科杂志,2013,12(9):688-691.
[1] 陈进宏. 腹腔镜活体供肝获取规范与创新[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 324-324.
[2] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国活体肝移植供者微创手术技术指南(2024版)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 241-252.
[3] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[4] 仲福顺, 余露, 范晓礼, 叶啟发. 肝移植治疗肝上皮样血管内皮瘤一例[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 293-297.
[5] 刘冉佳, 崔向丽, 周效竹, 曲伟, 朱志军. 儿童肝移植受者健康相关生存质量评价的荟萃分析[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 302-309.
[6] 贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[7] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[8] 王淑贤, 张良灏, 王利君, 张慧, 郭源, 许传屾, 李志强, 蔡金贞, 解曼, 饶伟. 成人肝移植围手术期严重心血管事件危险因素分析及预测模型研究[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 222-229.
[9] 张丽娜, 邢建坤, 张梁, 李云生, 王兢, 孙丽莹, 朱志军. 婴幼儿活体肝移植受者术中麻醉护理单中心经验[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 235-238.
[10] 黄建朋, 邹建强, 宗华. 肝移植术后腹壁疝诊治初步经验[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 471-473.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 傅斌生, 冯啸, 杨卿, 曾凯宁, 姚嘉, 唐晖, 刘剑戎, 魏绪霞, 易慧敏, 易述红, 陈规划, 杨扬. 脂肪变性供肝在成人劈离式肝移植中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 789-794.
[14] 中华医学会器官移植学分会, 中华医学会外科学分会外科手术学学组, 中华医学会外科学分会移植学组, 华南劈离式肝移植联盟. 劈离式供肝儿童肝移植中国临床操作指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 593-601.
[15] 刘军, 丘文静, 孙方昊, 李松盈, 易述红, 傅斌生, 杨扬, 罗慧. 在体与离体劈离式肝移植在儿童肝移植中的应用比较[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 688-693.
阅读次数
全文


摘要